岡　慎一  
     
2011

Watanabe T, Murakoshi H, Gatanaga H, Koyanagi M, Oka S, and Takiguchi M. Effective recognition of HIV-1-infected cells by HIV-1 integrase-specific HLA-B*4002-restricted T cells. Microbes Infect. 13(2):160-166, 2011
Honda K, Zheng N, Murakoshi H, Hashimoto M, Sakai K, Borghan MA, Chikata T, Koyanagi M, Tamura Y, Gatanaga H, Oka S, and Takiguchi M. Selection of escape mutant by HLA-C-restricted HIV-1 Pol-specific cytotoxic T lymphocytes carrying strong ability to suppress HIV-1 replication. Eur J Immunol. 41(1):97-106, 2011.

Honda M, Ishisaka M, Ishizuka N, Kimura S, Oka S on behalf of Japanese Anti-HIV-1 QD Study Group. Open-label randomized multicenter selection study of once daily antiretroviral treatment regimen comparing ritonavir boosted atazanavir to efavirenz with fixed dose abacavir and lamivudine. Intern Med. in press
Nakamura H, Teruya K, Takano M, Tsukada K, Tanuma J, Yazaki H, Honda H, Honda M, Gatanaga H, Kikuchi Y, and Oka S. Clinical symptoms and courses of primary HIV-1 infection in recent years in Japan. Intern Med. 50(2):95-101, 2011
 
2010
Tanuma J, Hachiya A, Ishigaki K, Gatanaga H, Lien TTM, Hien ND, Kin NV, Kaku M, and Oka S. Impact of CRF01_AE-specific polymorphic mutations G335D and A371V in the connection subdomain of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on susceptibility to nucleoside RT inhibitors. Microbes Infect. 12(14-15):1170-1177, 2010.

Mwimanzi P, Hasan Z, Tokunaga M, Gatanaga H, Oka S, and Ueno T. Naturally arising HIV-1 Nef variants conferring escape from cytotoxic T lymphocytes influence viral entry co-receptor expression and susceptibility to superinfection. Biochem Biophys Res Commun. 403(3-4):422-427, 2010.
Kawashima Y*, Kuse N*, Gatanaga H*, Naruto T, Fujiwara M, Dohki S, Akahoshi T, Maenaka K, Goulder P, Oka S, and Takiguchi M (*equal contribution). Long-term control of HIV-1 in hemophiliacs carrying slow-progressing allele HLA-B*5101. J Virol. 84(14):7151-7160, 2010.

Koizumi H*, Hashimoto M*, Fujiwara M, Murakoshi H, Chikata T, Borghan MA, Hachiya A, Kawashima Y, Takata H, Ueno T, Oka S, and Takiguchi M (*equal contribution). Different in vivo effects of HIV-1 immunodominant epitope-specific cytotoxic T lymphocytes on selection of escape mutant viruses. J Virol. 84(11):5508-5519, 2010.

Sakai K, Gatanaga H, Takata H, Oka S, and Takiguchi M. Comparison of CD4+ T-cell-subset distribution in chronically infected HIV+ patients with various CD4 nadir counts. Microbes Infect. 12(5):374-381, 2010.

Hashimoto M, Kitano M, Honda K, Koizumi H, Dohki S, Oka S, and Takiguchi M.  Selection of escape mutation by Pol154-162-specific cytotoxic T cells among chronically HIV-1-infected HLA-B*5401-positive individuals. Hum Immunol. 71(2):123-127, 2010.

Gatanaga H, Oowa M, and Oka S. Introduction of TaqMan HIV-1 assay increased unnecessary drug resistance testing. AIDS Patient Care STDS. 24(4):203-204, 2010.

Gatanaga H, Ode H, Hachiya A, Hayashida T, Sato H, Takiguchi M, and Oka S. Impact of human leukocyte antigen-B*51-restricted cytotoxic T-lymphocyte pressure on mutation patterns of nonnucleoside reverse transcriptase inhibitor resistance. AIDS. 24(5):Fast Track15-22, 2010.
Gatanaga H, Ode H, Hachiya S, Hayashida T, Sato H, and Oka S. Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine. Antimicrob Agents Chemother. 54(4):1596-1602, 2010.

Tsukada K, Teruya K, Tasato D, Gatanaga H, Kikuchi Y, and Oka S. Raltegravir-associated perihepatitis and peritonitis: a single case report. AIDS. (correspondence) 24(1):160-161, 2010.
 
2009
Watanabe T, Yasuoka A, Tanuma J, Yazaki H, Honda H, Tsukada K, Honda M, Gatanaga H, Teruya K, Kikuchi Y, and Oka S. Serum (1-->3) beta-D-glucan as a noninvasive adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with AIDS. Clin Infect Dis. 49(7):1128-1131, 2009.
Davaalkham J, Hayashida T, Tsuchiya K, Gatanaga H, Nyamkhuu D, and Oka S. Allele and Genotype Frequencies of Cytochrome P450 2B6 Gene in a Mongolian Population. Drug Metab Dispos. 37(10):1991-1993, 2009.
Watanabe K, Honda M, Watanabe T, Tsukada K, Teruya K, Kikuchi Y, Oka S, and Gatanaga H. Emergence of raltegravir-resistant HIV-1 in the central nerve system. Int J STD AIDS. (case report) in press

Zheng N, Fujiwara M, Ueno T, Oka S, and Takiguchi M. Strong ability of Nef-specific CD4+ cytotoxic T cells to suppress human immunodeficiency virus type 1 (HIV-1) replication in HIV-1-infected CD4+ T cells and macrophages. J Virol. 83(15):7668-7677, 2009.
Kamimura M, Watanabe K, Kobayakawa M, Mihara F, Edamoto Y, Teruya K, Kikuchi Y, and Oka S. Successful absorption of antiretroviral drugs after gastrojejunal bypass surgery following failure of therapy through a jejunal tube. Intern Med. (Case Report) 48(12):1103-1104, 2009.
Davaalkham J, Unenchimeng P, Baigalmaa Ch, Oyunbileg B, Tsuchiya K, Hachiya A, Gatanaga H , Nyamkhuu D, and Oka S. High-risk status of HIV-1 infection in the very low epidemic country, Mongolia, 2007. Int J STD AIDS. 20(6):391-394, 2009.

Ishizaki A, Cuong NH, Thuc PV, Trung NV, Saijoh K, Kageyama S, Ishigaki K, Tanuma J, Oka S, and Ichimura H. Profile of HIV type 1 infection and genotypic resistance mutations to antiretroviral drugs in treatment-naive HIV type 1-infected individuals in Hai Phong, Viet Nam. AIDS Res Hum Retroviruses. 25(2):175-182, 2009. 

Hachiya A, Shimane K, Sarafianos SG, Kodama EN, Sakagami Y, Negishi F, Koizumi H, Gatanaga H, Matsuoka M, Takiguchi M, and Oka S. Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment- naïve patients. Antiviral Res. 82(3):115-121, 2009.

Kawashima Y, Pfafferott K, Frater J, Matthews P, Payne R, Addo M, Gatanaga H, Fujiwara M, Hachiya A, Koizumi H, Kuse N, Oka S, Duda A, Prendergast A, Crawford H, Leslie A, Brumme Z, Brumme C, Allen T, Brander C, Kaslow R, Tang J, Hunter E, Allen S, Mulenga J, Branch S, Roach T, John M, Mallal S, Ogwu A, Shapiro R, Prado JG, Fidler S, Weber J, Pybus OG, Klenerman P, Ndung’u T, Phillips R, Heckerman D, Harrigan PR, Walker BD, Takiguchi M*, and Goulder P* (*equally contribution). Adaptation of HIV-1 to Human Leukocyte Antigen class I. Nature 458(7238): 641-645, 2009.
Murakoshi H, Kitano M, Akahoshi T, Kawashima Y, Dohki S, Oka S, and Takiguchi M.  Identification and characterization of 2 HIV-1 Gag immunodominant epitopes restricted by Asian HLA allele HLA-B*4801. Hum Immunol. 70(3):170-174, 2009.
Koizumi H, Iwatani T, Tanuma J, Fujiwara M, Izumi T, Oka S, and Takiguchi M.  Escape mutation selected by Gag28-36-specific cytotoxic T cells in HLA-A*2402-positive HIV-1-infected donors. Microbes Infect. 11(2):198-204, 2009.
Gatanaga H, and Oka S. Successful genotype-tailored treatment with small-dose efavirenz. AIDS. (correspondence) 23(3):433-434, 2009.

Gatanaga H, Tsukada K, Honda H, Tanuma J, Yazaki H, Watanabe T, Honda M, Teruya K, Kikuchi Y, and Oka S. Detection of HIV type 1 load by the Roche Cobas TaqMan assay in patients with viral loads previously undetectable by the Roche Cobas Amplicor Monitor. Clin Infect Dis. (correspondence) 48(2):260-262, 2009.

Bi X, Suzuki Y, Gatanaga H, and Oka S. High frequency and proliferation of CD4+ FOXP3+ Treg in HIV-1-infected patients with low CD4 counts. Eur J Immunol. 39(1):301-309, 2009.

 
2008

Kitano M, Kobayashi N, Kawashima Y, Akahoshi T, Nokihara K, Oka S, and Takighuchi M. Identification and characterization of HLA-B*5401-restricted HIV-1-Nef and Pol-specific CTL epitopes. Microbes Infect. 10(7):764-772, 2008.

Tanuma J, Fujiwara M, Teruya K, Matsuoka S, Yamanaka H, Gatanaga H, Tachikawa N, Kikuchi Y, Takiguchi M, and Oka S. HLA-A*2402-restricted HIV-1-specific cytotoxic T lymphocytes and escape mutation after ART with structured treatment interruptions. Microbes Infect. 10(6):689-698, 2008.

Hachiya A, Kodama EN, Sarafianos SG, Schuckmann MM, Sakagami Y, Matsuoka M, Takiguchi M, Gatanaga H, and Oka S. Amino Acid Mutation N348I in the Connection Subdomain of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confers Multiclass Resistance to Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitors. J Virol. 82(7):3261-3270, 2008.

Ueno T, Motozono C, Douki S, Mwimanzi P, Rauch S, Fackler OT, Oka S, and Takiguchi M. CTL-mediated selective pressure influences dynamic evolution and pathogenic functions of HIV-1 Nef. J Immunol. 180(2):1107-1116, 2008.

Kawashima Y, Satoh M, Oka S, Shirasaka T, and Takiguchi M. Different immunodominance of HIV-1-specific CTL epitopes among three subtypes of HLA-A*26 associated with slow progression to AIDS. Biochem Biophys Res Commun. 366(3):612-616, 2008.
Fujiwara M, Tanuma J, Koizumi H, Kawashima Y, Honda K, Mastuoka-Aizawa S, Dohki S, Oka S, and Takiguchi M. Different Abilities of Escape Mutant-Specific Cytotoxic T Cells to Suppress Replication of Escape Mutant and Wild-type HIV-1 in New Hosts. J Virol. 82(1):138-147, 2008.

Hayashida T, Gatanaga H, Tanuma J, and Oka S. Effect of low HIV type 1 load and antiretroviral treatment on IgG-capture BED-enzyme immunoassay. AIDS Res Hum Retroviruses. 24(3):495-498, 2008.

 
←Back